Developing microRNAs as engineering tools to modulate monoclonal antibody galactosylation
Biotechnology and Bioengineering · 2024
DOI: 10.1002/bit.28616 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, 2024. Verfasst von Florian Klingler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Applied Biotechnology, University of Applied Sciences Biberach, Biberach, Germany. Hauptthemen laut MEDLINE: MicroRNAs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
N‐linked glycosylation is one of the most important post‐translational modifications of monoclonal antibodies (mAbs) and is considered to be a critical quality attribute (CQA), as the glycan composition often has immunomodulatory effects. Since terminal galactose residues of mAbs can affect antibody‐dependent cellular cytotoxicity (ADCC), complement‐dependent cytolysis (CDC) activation, serum half‐life, and antiviral activity it has to be monitored, controlled and modulated to ensure therapeutic effects. The ability of small noncoding microRNAs (miRNAs) to modulate glycosylation in Chinese hamster ovary (CHO) production cells was recently reported establishing miRNAs as engineering tools for modulation of protein glycosylation. In this study, we report the characterization and validation of miRNAs as engineering tools for increased (mmu‐miR‐452‐5p, mmu‐miR‐193b‐3p) or decreased (mmu‐miR‐7646‐5p, mmu‐miR‐7243‐3p, mmu‐miR‐1668, mmu‐let‐7c‐1‐3p, mmu‐miR‐7665‐3p, mmu‐miR‐6403) degree of galactosylation. Furthermore, the biological mode of action regulating gene expression of the galactosylation pathway was characterized as well as their influence on bioprocess‐related parameters. Most important, stable plasmid‐based overexpression of these miRNAs represents a versatile tool for engineering N‐linked galactosylation to achieve favorable phenotypes in cell lines for biopharmaceutical production.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Applied Biotechnology, University of Applied Sciences Biberach, Biberach, Germany.
- Department of Chemistry, Aalen University, Aalen, Germany.
ORCID-Profile: Florian Klingler, Patrick Schlossbauer
Förderung
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Klingler, F., Schlossbauer, P., Naumann, L., Handrick, R., Hesse, F., Neusüß, C., & Otte, K. (2024). Developing microRNAs as engineering tools to modulate monoclonal antibody galactosylation. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28616
Vancouver
Klingler F, Schlossbauer P, Naumann L, Handrick R, Hesse F, Neusüß C, et al. Developing microRNAs as engineering tools to modulate monoclonal antibody galactosylation. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28616
BibTeX
@article{Klingler2024,
author = {Klingler, Florian and Schlossbauer, Patrick and Naumann, Lukas and Handrick, René and Hesse, Friedemann and Neusüß, Christian and Otte, Kerstin},
title = {Developing microRNAs as engineering tools to modulate monoclonal antibody galactosylation},
journal = {Biotechnology and Bioengineering},
year = {2024},
doi = {10.1002/bit.28616}
}
EUVIMED